Atlas Trials

Liposomal Irinotecan in Combination With Oxaliplatin and S-1 Versus Gemcitabine Combined With Capecitabine as Postoperative Adjuvant Therapy for Pancreatic Cancer

Clinical trial NCT06571461 · NOT_YET_RECRUITING

Trial details

NCT number
NCT06571461
Sponsor
CSPC Ouyi Pharmaceutical Co., Ltd.
Status
NOT_YET_RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Pancreatic Cancer
Start date
2024-09-01
Primary completion
2028-01-01
Enrollment
408

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.